Phase I dose-escalation trial of high-dose melphalan (M) with palifermin (P) for cytoprotection followed by autologous stem cell transplantation (ASCT) for myeloma (MM) patients with normal renal function (NRF)

Category Primary study
JournalJournal of Clinical Oncology
Year 2010
This article has no abstract
Epistemonikos ID: fdd324f9b8d82e03f0711f89684d17410c7c8903
First added on: Mar 01, 2025